What Has Been the Progress and Growth of the Neurological Disorder Drugs Market in Recent Years?
The neurological disorder drugs market has seen considerable growth due to a variety of factors.
• The neurological disorder drugs market has experienced significant growth in recent years. It will rise from $84.6 billion in 2024 to $90.09 billion in 2025, at a CAGR of 6.5%.
This growth is due to increased animal testing with positive results, expanding therapeutic treatments, rising neurological issues, government initiatives, and increased healthcare expenditure.
How Does the Forecast Look for the Neurological Disorder Drugs Market?
The neurological disorder drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The neurological disorder drugs market is expected to grow to $114.65 billion by 2029 at a CAGR of 6.2%.
Growth is driven by expanding therapeutic options, disease-modifying treatments, and the increasing prevalence of neurological diseases. Key trends include advancements in drug design, neuroimaging, genetic research, and collaborations between market players.
What Are The Leading Drivers Of Growth In The Neurological Disorder Drugs Market?
The increasing prevalence of neurological disorders is expected to propel the growth of the neurological disorder drugs market. Neurological disorders are on the rise due to aging populations and greater exposure to environmental and lifestyle risk factors. Neurological disorder drugs help manage these complex conditions by alleviating symptoms, slowing disease progression, and improving patient outcomes. For example, in September 2024, the Australian Institute of Health and Welfare projected the number of individuals with dementia in Australia would more than double by 2058, further increasing demand for neurological disorder drugs.
How Are The Segments Defined Within The Global Neurological Disorder Drugs Market?
The neurological disorder drugs market covered in this report is segmented –
1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes
2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users
Subsegtments:
1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine
2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists
3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics
4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic
5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications
Pre-Book The Neurological Disorder Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Neurological Disorder Drugs Industry?
Major pharmaceutical firms active in the neurological disorder drugs market are concentrating on creating innovative therapies using Ocrelizumab to boost treatment effectiveness, enhance patient results, and broaden therapy choices for those with multiple sclerosis. As a humanized monoclonal antibody, Ocrelizumab is utilised in medically treating multiple sclerosis (MS), a type of neurological condition. For instance, Roche Holding AG, a Swiss pharmaceutical enterprise, introduced Ocrevus (Ocrelizumab) in India in February 2024. This is a fresh disease-modifying therapy (DMT) for people with multiple sclerosis. Ocrevus, backed by over 10 years of clinical and real-world evidence, is the first-ever DMT to receive approval for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). As a monoclonal antibody, it targets CD20-positive B cells considered to be involved in the auto-immune assault on the nervous system in MS cases. It is used to address both forms of the disease, RRMS and PPMS, thus becoming the first drug to receive approval for these MS types. It is generally administered intravenously every six months and its clinical trials have demonstrated effectiveness in reducing disease activity and slowing down disability progression.
Who Are the Key Players In The Neurological Disorder Drugs Market?
Major companies operating in the neurological disorder drugs market are:
• F. Hoffmann-La Roche Ltd
• Bayer AG
• Sanofi S.A
• AstraZeneca PLC
• Abbott Laboratories
• Novartis AG
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company Pvt Ltd
• Amgen Inc
• Boehringer Ingelheim GmbH
• Novo Nordisk A/S
• Merck KGaA
• Teva Pharmaceutical Industries Ltd
• Otsuka America Pharmaceutical Inc
• Biogen Inc
• Bausch Health Companies Inc
• Alexion Pharmaceuticals Inc.
• UCB S.A.
• Eisai Co Ltd
• Cipla Inc
• BioMarin Pharmaceutical Inc.
• Biocon Ltd
• Acorda Therapeutics Inc.
What Is The Most Dominant Region In The Neurological Disorder Drugs Market?
North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
